Purpose To investigate the clinical impact of three available antivirals for early COVID-19
treatment in a large real-life cohort. Methods Between January and October 2022 all …

nCoV pandemic has influenced on millions of people's life across the world, which is caused
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease …

Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although
most are not well established; among these are several small molecule antiviral agents …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

Abstract Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …

Early treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or
second-line therapy (molnupiravir) prevents hospitalization and death among patients with …

Objectives Evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults
with COVID-19. Data sources Electronic search for eligible articles of PubMed, Cochrane …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …